A Research Study to See How Semaglutide Helps People With Excess Weight and Type 2 Diabetes Lose Weight

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 512 participants.

Also called NCT05649137

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 512 participants (enrolled count) (from the registry)
Sponsor
  • Novo Nordisk Registry lists this organization as the lead sponsor
Registry
  • NCT NCT05649137
  • EudraCT 2022-002235-60
Other papers using this trial's data
  • Once-weekly semaglutide 7·2 mg in adults with obesity and type 2 diabetes (STEP UP T2D): a randomised, controlled, phase 3b trial The lancet. Diabetes & endocrinology, 2025-11 DOI, PubMed 40961953 PubMed links an erratum for this paper. Erratum: PMID 41932351

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Bulgaria, Canada, Hungary, Poland, Portugal, Slovakia, South Africa (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05649137. Randomized; quadruple masking; primary purpose treatment. Start 2023-01-04 (actual); primary completion 2024-10-28 (actual). Results posted on 2026-04-27.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Research Study to See How Semaglutide Helps People With Excess Weight and Type 2 Diabetes Lose Weight
Condition
Obesity
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Semaglutide
Intervention (Drug)
Semaglutide
Intervention (Drug)
Placebo
Lead sponsor
Novo Nordisk A/S (class: industry)

Record details

Record id
cardio:ct-nct05649137
Content hash
558f78f717417c29bf42719c47e8d75fbaa681111ea9b25f5c51fe3d3fe39dd2